Role of Anaerobes in Crohn’s Disease

  • Dan Danielsson


Crohn’s disease is an idiopathic chronic inflammatory disease of the bowel. Ulcerative colitis is the other main disease of this group, Crohn et al. (4) described this syndrome as regional or terminal ileitis. They recognized an acute type of short duration usually followed by spontaneous recovery; and a chronic type of longer duration. This basic definition is valid today. It has been convincingly shown that the acute type is an entirely separate entity from the chronic form (14). Yersinia enterocolitica is the etiologic agent in at least 50–60% of the acute cases in Sweden (14).


Ulcerative Colitis Terminal Ileum Erythema Multiforme Yersinia Enterocolitica Acute Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    Belsheim, J., H. Gnarpe, and S. Persson. 1978. Influence of metronidazole and timidazole on leucocyte Chemotaxis in Crohn’s disease. Infection 6 (Suppl. 1): 107.CrossRefGoogle Scholar
  2. 2.
    Brandtzaeg, P., and K. Baklien. 1976. Immunohistochemical studies on the formation and epithelial transport of immunoglobulins in normal and diseased human intestinal mucosa. Scand. J. Gastroent. 11 (Suppl. 36): 1–45.Google Scholar
  3. 3.
    Campbell, D.E.S. 1973. New findings on the pharmacokinetics and pharmacology of sulfasalazine. Lakartidningen 70: 3068–3071.Google Scholar
  4. 4.
    Crohn, B.B., L. Ginzburg, and G.D. Oppenheimer. 1932. Regional ileitis. A pathologic and clinical entity. JAMA 99: 1323–1329.Google Scholar
  5. 5.
    Danielsson, D., and S. Persson. 1978. Antibacterial activity of Azathioprine (Imuran) against anaerobic intestinal bacteria: implications in Crohn’s disease. Curr. Chemother. 295–298.Google Scholar
  6. 6.
    Danielsson, D., J. Kjellander, S. Persson, and S. Wallensten. 1979. Investigation of the immune response to aerobic and anaerobic intestinal bacteria in a patient with Crohn’s disease. Scand. J. Infect. Dis. (Suppl. 19 ): 52–60.Google Scholar
  7. 7.
    Elion, G.B., S.W. Callahan, G.H. Hitchings, R.W. Rundles, and J. Laszlo. 1962. Experimental, clinical and metabolic studies of thiopurines. Cancer Chemother. Rep. 16: 167–202.Google Scholar
  8. 8.
    Kraft, S.C., and J.B. Kirsner. 1975. The immunology of ulcerative colitis and Crohn’s disease: clinical and humoral aspects, p. 60–80. In J.B. Kirsner and R.G. Shorter (ed.), Inflammatory bowel disease. Lea and Febiger, Philadelphia.Google Scholar
  9. 9.
    Krook, A., D. Danielsson, J. Kjellander, and G. Jârnerot. 1979. Changes in the fecal flora of patients with Crohn’s disease during treatment with metronidazole. Scand. J. Gastroent. (In press).Google Scholar
  10. 10.
    Lagercrantz, R., S. Hammarstrom, P. Perlmann, and B.E. Gustavsson. 1966. Immunological studies in ulcerative colitis. III. Incidence of antibodies to colon-antigen in ulcerative colitis and other gastro-intestinal disease. Clin. Exp. Immunol. 1: 263–276.PubMedGoogle Scholar
  11. 11.
    O’Donoghue, D.P., A.M. Dawson, J. Powell-Tuck, and R.L. Brown. 1978. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet ii: 955–957.Google Scholar
  12. 12.
    Rosenberg, J.L., B. Levin, A.J. Wall, and J.B. Kirsner. 1975. A controlled trial of azathioprine in Crohn’s disease. Am. J. Dig. Dis. 20: 721–726.PubMedCrossRefGoogle Scholar
  13. 13.
    Persson, S., and D. Danielsson. 1973. Studies on Crohn’s disease II. Immunoglobulin-containing cells in the terminal ileum. Acta. Chir. Scand. 139: 735–738.PubMedGoogle Scholar
  14. 14.
    Persson, S., D. Danielsson, J. Kjellander, and S. Wallensten. 1976. Studies on Crohn’s disease. I. The relationship between Yersinia enterocolitica infection and terminal ileitis. Acta. Chir. Scand. 142: 84–90.PubMedGoogle Scholar
  15. 15.
    Persson, S., and D. Danielsson. 1979. On the occurrence of serum antibodies to Bacteroides fragilis and serogroups of E. coli in patients with Crohn’s disease. Scand. J. Infect. Dis. (Suppl. 19 ): 61–67.Google Scholar
  16. 16.
    Perlmann, P., S. Hammarstrom, R. Lagercrantz, and D. Campbell. 1967. Autoantibodies to colon in rats and human ulcerative colitis: Cross reactivity with Escherichia coli 0:14 antigen. Proc. Soc. Exp. Biol. Med. 125: 975–980.PubMedGoogle Scholar
  17. 17.
    Perlmann, P., and O. Broberger. 1969. Lower gastrointestinal system, p. 551-561. _In P.A. Miescher and H.J. Muller-Eberhard (ed.), Textbook of immunopathology, Vol. 2. Grune and Stratton, New York.Google Scholar
  18. 18.
    Shorter, R.G., K.A. Huizenga, and R.J. Spencer. 1972. A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Am. J. Dig. Dis. 17: 1024–1032.PubMedCrossRefGoogle Scholar
  19. 19.
    Thayer, W.R., M. Brown, M.H. Sangree, J. Katz, and T. Hersh. 1969. Escherichia coli 0:14 and colon hemagglutinating antibodies in inflammatory bowel disease. Gastroenterology 57: 311–318.Google Scholar
  20. 20.
    Ursing, B., and C. Kamme. 1975. Metronidazole in Crohn’s disease. Lancet 1: 775–777.PubMedCrossRefGoogle Scholar
  21. 21.
    Watson, D.W., and R.G. Shorter. 1975. The immunology of ulcerative colitis and Crohn’s disease: Cell-mediated immune response, p. 81 – 89. In J.B. Kirsner and R.G. Shorter (ed.), Inflammatory bowel disease. Lea and Febiger, Philadelphia.Google Scholar
  22. 22.
    Willoughby, J.M.T., P.J. Kumar, J. Beckett, and A.M. Dawson. 1971. A controlled trial of azathioprine in Crohn’s disease. Lancet ii: 944–946.Google Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • Dan Danielsson
    • 1
  1. 1.Department of Clinical Bacteriology and ImmunologyCentral County HospitalÖrebroSweden

Personalised recommendations